60 Degrees Pharmaceuticals, Inc. (SXTP)
After hours:
| Previous close | 0.2871 |
| Open | 0.2900 |
| Bid | 0.0000 x 0 |
| Ask | 0.2920 x 1200 |
| Day's range | 0.2709 - 0.2981 |
| 52-week range | 0.2010 - 8.6500 |
| Volume | |
| Avg. volume | 260,170 |
| Market cap | 3.468M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9900 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.30 |
GlobeNewswire60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infectionsProminent researchers/clinicians in the tick-borne disease scientific community postulate that latent Babesia spp infections may trigger CFS symptomsPlanned study at North Carolina State College of Veterinary Medicine will assess whether Babesia spp parasites are present in samples from patients with chronic fatigue/neurologic symptoms by PCRCDC estimates CFS affects 3.3 million Americans WASHINGT
- GlobeNewswire
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand.Gross profit increased from ($55.9 thousand) to $51.0 thousand. WASHINGTON, May 15, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2024 year, ended March 31, 2024. Financial Highlights for the Quarter Ended Marc
- GlobeNewswire
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness.The upcoming 60 Degrees Pharma clinical trial of tafenoquine in treating babesiosis will be the first and only such study to date.Enrollment is planned to begin in summer 2024.The Journal of Infectious Diseases has published a letter outlining the planned trial protocol. WASHINGTON, May 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NA
